| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00330-006-0425-9 |
| P698 | PubMed publication ID | 17072618 |
| P50 | author | Giuseppe Giaccone | Q37829946 |
| Martijn R Meijerink | Q43182951 | ||
| P2093 | author name string | Radu A Manoliu | |
| Hester van Cruijsen | |||
| Klaas Hoekman | |||
| Jan Hein T M van Waesberghe | |||
| Matthijs Kater | |||
| Cors van Schaik | |||
| P2860 | cites work | Tumor angiogenesis: therapeutic implications | Q27860595 |
| New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 | ||
| AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer | Q28251373 | ||
| Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy | Q29547379 | ||
| Toxicity and response criteria of the Eastern Cooperative Oncology Group | Q29619399 | ||
| Quantitative perfusion map of malignant liver tumors, created from dynamic computed tomography data | Q30907241 | ||
| 62Cu-PTSM and PET used for the assessment of angiotensin II-induced blood flow changes in patients with colorectal liver metastases | Q32002205 | ||
| Hepatic perfusion parameters in chronic liver disease: dynamic CT measurements correlated with disease severity | Q32061742 | ||
| Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. | Q33744660 | ||
| Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial | Q34271566 | ||
| Perfusion imaging of the liver: current challenges and future goals | Q34398265 | ||
| Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. | Q34533636 | ||
| Imaging angiogenesis: applications and potential for drug development | Q36027611 | ||
| The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. | Q36616812 | ||
| Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer | Q37219981 | ||
| Rim enhancement in colorectal metastases at CT during infusion hepatic arteriography. Does it represent liver parenchyma or live tumor cell zone? | Q39447358 | ||
| A physiologic imaging pilot study of breast cancer treated with AZD2171. | Q40333245 | ||
| Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. | Q40479307 | ||
| Improving the detection of hepatic metastases by the use of dynamic flow scintigraphy | Q41509313 | ||
| First-pass measurements of regional blood flow with external detectors | Q41585516 | ||
| Colour perfusion imaging: a new application of computed tomography | Q41787650 | ||
| Evaluation of the anti-vascular effects of combretastatin in rodent tumours by dynamic contrast enhanced MRI. | Q43900373 | ||
| Measuring portal venous perfusion with contrast-enhanced CT: comparison of direct and indirect methods | Q43914801 | ||
| Perfusion of colorectal hepatic metastases. Relative distribution of flow from the hepatic artery and portal vein | Q44266901 | ||
| The portal component of hepatic perfusion measured by dynamic CT: an indicator of hepatic parenchymal damage | Q44762666 | ||
| Perfusion CT in patients with advanced bronchial carcinomas: a novel chance for characterization and treatment monitoring? | Q44804423 | ||
| Measurement of tissue perfusion by dynamic computed tomography | Q44997256 | ||
| Measurement of regional cerebral blood flow using ultrafast computed tomography. Theoretical aspects. | Q46036593 | ||
| MRI assessment of microvascular characteristics in experimental breast tumors using a new blood pool contrast agent (MS-325) with correlations to histopathology. | Q46089577 | ||
| Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer | Q46468963 | ||
| Assessment of inter- and intrapatient variability in C15O2 positron emission tomography measurements of blood flow in patients with intra-abdominal cancers. | Q47297737 | ||
| Tumor perfusion rate determined noninvasively by dynamic computed tomography predicts outcome in head-and-neck cancer after radiotherapy | Q47373010 | ||
| Breath-hold perfusion and permeability mapping of hepatic malignancies using magnetic resonance imaging and a first-pass leakage profile model. | Q51725613 | ||
| Non-invasive quantification of liver perfusion with dynamic computed tomography and a dual-input one-compartmental model. | Q52070479 | ||
| Derivation of gamma variate indicator dilution function from simple convective dispersion model of blood flow. | Q52431974 | ||
| Cerebral blood flow determination by rapid-sequence computed tomography: theoretical analysis. | Q52751958 | ||
| A phase I surrogate endpoint study of SU6668 in patients with solid tumors. | Q53615730 | ||
| Early modifications of hepatic perfusion measured by functional CT in a rat model of hepatocellular carcinoma using a blood pool contrast agent | Q59510517 | ||
| Reproducibility of quantitative dynamic MRI of normal human tissues | Q62612608 | ||
| Quantification of perfusion of liver tissue and metastases using a multivessel model for replenishment kinetics of ultrasound contrast agents. | Q64025807 | ||
| Hepatic perfusion changes in mice livers with developing colorectal cancer metastases. | Q64948664 | ||
| Liver perfusion studied with ultrafast CT | Q72334213 | ||
| Functional images of hepatic perfusion obtained with dynamic CT | Q72822410 | ||
| Splenic blood flow: evaluation with computed tomography | Q73090288 | ||
| CT assessment of cerebral perfusion: experimental validation and initial clinical experience | Q73130085 | ||
| Lung nodule enhancement at CT: multicenter study | Q73375528 | ||
| 9:00-9:15. Antiangiogenic Treatment with Endostatin Results in Uncoupling of Blood Flow and Glucose Metabolism in Human Tumors | Q73379275 | ||
| A CT method to measure hemodynamics in brain tumors: validation and application of cerebral blood flow maps | Q73578659 | ||
| Solitary pulmonary nodules: evaluation of blood flow patterns with dynamic CT | Q73843574 | ||
| Colorectal cancer: diagnostic potential of CT measurements of hepatic perfusion and implications for contrast enhancement protocols | Q73931348 | ||
| Reproducibility of quantitative CT perfusion imaging | Q74222592 | ||
| In vivo assessment of neovascularization of liver metastases using perfusion CT | Q74620633 | ||
| Development of perfusion CT software for personal computers | Q74627069 | ||
| The theory and applications of the exchange of inert gas at the lungs and tissues | Q75726399 | ||
| Does the presence of distant and local malignancy alter parenchymal perfusion in apparently disease-free areas of the liver? | Q77073447 | ||
| Assessment of hepatic perfusion parameters with dynamic MRI | Q77382106 | ||
| Regional blood flow, capillary permeability, and compartmental volumes: measurement with dynamic CT--initial experience | Q77785612 | ||
| CT measurement of perfusion and permeability within lymphoma masses and its ability to assess grade, activity, and chemotherapeutic response | Q78086655 | ||
| Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors | Q78785324 | ||
| P433 | issue | 7 | |
| P304 | page(s) | 1700-1713 | |
| P577 | publication date | 2006-10-27 | |
| P1433 | published in | European Radiology | Q5413071 |
| P1476 | title | The use of perfusion CT for the evaluation of therapy combining AZD2171 with gefitinib in cancer patients | |
| P478 | volume | 17 |
| Q35798947 | Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlled, phase 1 trial. |
| Q47552136 | Appraisal of radiation dose with 64-slice computed tomography perfusion in lung cancer patients with special reference to SSDE: An initial experience in a tertiary care hospital |
| Q51853080 | Assessment of the spatial pattern of colorectal tumour perfusion estimated at perfusion CT using two-dimensional fractal analysis. |
| Q37693472 | CT perfusion in oncology: how to do it. |
| Q36558272 | CTA combined with CT perfusion for assessing the efficacy of anti-angiogenic therapy in rabbit VX2 tumors |
| Q45001364 | CTA-enhanced perfusion CT: an original method to perform ultra-low-dose CTA-enhanced perfusion CT. |
| Q44939902 | Can perfusion CT assessment of primary colorectal adenocarcinoma blood flow at staging predict for subsequent metastatic disease? A pilot study |
| Q53268488 | Commercial software upgrades may significantly alter Perfusion CT parameter values in colorectal cancer. |
| Q36347036 | Comparison of free breathing versus breath-hold in perfusion imaging using dynamic volume CT |
| Q39647845 | Current status and guidelines for the assessment of tumour vascular support with dynamic contrast-enhanced computed tomography |
| Q57177411 | Dynamic contrast-enhanced CT for the assessment of tumour response in malignant pleural mesothelioma: a pilot study |
| Q34298000 | Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment? |
| Q30475764 | Estimation of intra-operator variability in perfusion parameter measurements using DCE-US. |
| Q26860708 | Functional imaging biomarkers for assessing response to treatment in liver and lung metastases |
| Q39814899 | Hepatic Perfusion Imaging: Concepts and Application |
| Q37356037 | Morphological and functional MDCT: problem-solving tool and surrogate biomarker for hepatic disease clinical care and drug discovery in the era of personalized medicine |
| Q42923595 | Perfusion CT and US of colorectal cancer liver metastases: a correlative study of two dynamic imaging modalities. |
| Q37707171 | Perfusion CT in solid body-tumours. Part II: Clinical applications and future development. |
| Q34427108 | Perfusion characterization of liver metastases from endocrine tumors: Computed tomography perfusion |
| Q33764784 | Perfusion magnetic resonance imaging of the liver |
| Q37392001 | Perfusion-CT monitoring of cryo-ablated renal cells tumors |
| Q33796799 | Protocol modifications for CT perfusion (CTp) examinations of abdomen-pelvic tumors: impact on radiation dose and data processing time |
| Q46693507 | Quantitative mapping of hepatic perfusion index using MR imaging: a potential reproducible tool for assessing tumour response to treatment with the antiangiogenic compound BIBF 1120, a potent triple angiokinase inhibitor. |
| Q33857343 | RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline |
| Q82495518 | Radiation dose from volumetric helical perfusion CT of the thorax, abdomen or pelvis |
| Q33567345 | Response Evaluation of Chemotherapy for Lung Cancer |
| Q34088696 | Targeted therapies in renal cell cancer: recent developments in imaging |
| Q53199563 | The value of perfusion CT in predicting the short-term response to synchronous radiochemotherapy for cervical squamous cancer. |
| Q51878570 | Total-liver-volume perfusion CT using 3-D image fusion to improve detection and characterization of liver metastases. |
| Q37760857 | Tracer kinetic modelling of tumour angiogenesis based on dynamic contrast-enhanced CT and MRI measurements |
Search more.